MX2019002664A - Proteina de union a antigeno contra her3. - Google Patents
Proteina de union a antigeno contra her3.Info
- Publication number
- MX2019002664A MX2019002664A MX2019002664A MX2019002664A MX2019002664A MX 2019002664 A MX2019002664 A MX 2019002664A MX 2019002664 A MX2019002664 A MX 2019002664A MX 2019002664 A MX2019002664 A MX 2019002664A MX 2019002664 A MX2019002664 A MX 2019002664A
- Authority
- MX
- Mexico
- Prior art keywords
- nucleic acid
- antigen binding
- binding protein
- present
- antigen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
La presente invención proporciona una proteína de unión a antígeno que se une específicamente a un epítopo conformacional formado por los dominios III y IV del receptor 3 del factor de crecimiento epidérmico humano (HER3) y proteínas de unión a antígeno que compiten con él por la unión, así como la proteína de fusión o el conjugado que los comprenden. La presente invención también proporciona una molécula de ácido nucleico que comprende una secuencia que codifica dichas proteínas de unión a antígeno, vectores que comprenden el ácido nucleico y células y productos farmacéuticos que comprenden la proteína de unión a antígeno, la proteína de fusión, el ácido nucleico o el vector. La presente invención también proporciona la proteína de unión a antígeno, la proteína de fusión o el conjugado, el ácido nucleico, el vector, la célula o el producto farmacéutico para su uso como medicamento. La presente invención proporciona además un procedimiento para inhibir el crecimiento de tumores o tratar el cáncer, que comprende administrar una cantidad terapéuticamente eficaz de la proteína de unión a antígeno, la proteína de fusión o el conjugado, el ácido nucleico, el vector, la célula o el producto farmacéutico.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16188871 | 2016-09-15 | ||
| PCT/EP2017/073328 WO2018050848A1 (en) | 2016-09-15 | 2017-09-15 | Antigen binding protein against her3 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019002664A true MX2019002664A (es) | 2019-09-26 |
Family
ID=57017956
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019002664A MX2019002664A (es) | 2016-09-15 | 2017-09-15 | Proteina de union a antigeno contra her3. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US11008402B2 (es) |
| EP (1) | EP3512886A1 (es) |
| JP (2) | JP7203426B2 (es) |
| KR (1) | KR102469700B1 (es) |
| CN (1) | CN110167968B (es) |
| AU (1) | AU2017327769B2 (es) |
| BR (1) | BR112019005001A2 (es) |
| CA (1) | CA3033694C (es) |
| MX (1) | MX2019002664A (es) |
| WO (1) | WO2018050848A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210022542A (ko) | 2018-04-11 | 2021-03-03 | 샐러브리스 바이오테라퓨틱스, 인크. | 인간 뉴레귤린-1(nrg-1) 재조합 융합 단백질 조성물 및 이의 사용 방법 |
| EP4034245A1 (en) * | 2019-09-25 | 2022-08-03 | Universität Stuttgart | Trivalent binding molecules |
| WO2023165475A1 (zh) * | 2022-03-03 | 2023-09-07 | 四川科伦博泰生物医药股份有限公司 | Her3结合蛋白及其用途 |
| CN115057946B (zh) * | 2022-06-30 | 2023-05-16 | 四川省医学科学院·四川省人民医院 | 干扰素在制备抗广谱流感病毒和冠状病毒药物中的应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
| US4704355A (en) | 1985-03-27 | 1987-11-03 | New Horizons Diagnostics Corporation | Assay utilizing ATP encapsulated within liposome particles |
| DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2 Inc | Geänderte antikörper. |
| WO1991004014A1 (en) | 1989-09-21 | 1991-04-04 | Synergen, Inc. | Method for transporting compositions across the blood brain barrier |
| SG48759A1 (en) | 1990-01-12 | 2002-07-23 | Abgenix Inc | Generation of xenogenic antibodies |
| US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| AU2003218600C1 (en) * | 2002-03-26 | 2009-12-17 | Zensun (Shanghai) Science & Technology Co., Ltd. | ERBB3 based methods and compositions for treating neoplasms |
| NO2719708T3 (es) * | 2009-11-13 | 2018-03-24 | ||
| CA2842860A1 (en) | 2011-07-28 | 2013-01-31 | Sea Lane Biotechnologies, Llc | Sur-binding proteins |
| AU2012346540C1 (en) * | 2011-11-30 | 2019-07-04 | Genentech, Inc. | ErbB3 mutations in cancer |
| BR112014013495A2 (pt) | 2011-12-05 | 2017-06-13 | Novartis Ag | anticorpos para o receptor 3 do fator de crescimento epidérmico (her3) direcionados para o domínio iii e domíniuo iv de her3 |
| JP2015534997A (ja) * | 2012-10-25 | 2015-12-07 | ソレント・セラピューティクス・インコーポレイテッドＳｏｒｒｅｎｔｏ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． | ＥｒｂＢ３と結合する抗原結合タンパク質 |
-
2017
- 2017-09-15 MX MX2019002664A patent/MX2019002664A/es unknown
- 2017-09-15 CA CA3033694A patent/CA3033694C/en active Active
- 2017-09-15 WO PCT/EP2017/073328 patent/WO2018050848A1/en unknown
- 2017-09-15 KR KR1020197009096A patent/KR102469700B1/ko active IP Right Grant
- 2017-09-15 US US16/326,864 patent/US11008402B2/en active Active
- 2017-09-15 BR BR112019005001A patent/BR112019005001A2/pt unknown
- 2017-09-15 CN CN201780057182.8A patent/CN110167968B/zh active Active
- 2017-09-15 JP JP2019514232A patent/JP7203426B2/ja active Active
- 2017-09-15 AU AU2017327769A patent/AU2017327769B2/en active Active
- 2017-09-15 EP EP17768777.9A patent/EP3512886A1/en active Pending
-
2022
- 2022-08-04 JP JP2022124782A patent/JP2022169589A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017327769B2 (en) | 2023-12-21 |
| US11008402B2 (en) | 2021-05-18 |
| KR20190065259A (ko) | 2019-06-11 |
| CA3033694C (en) | 2023-06-27 |
| CN110167968A (zh) | 2019-08-23 |
| AU2017327769A1 (en) | 2019-03-07 |
| EP3512886A1 (en) | 2019-07-24 |
| BR112019005001A2 (pt) | 2019-06-04 |
| CN110167968B (zh) | 2023-11-28 |
| JP2020501509A (ja) | 2020-01-23 |
| JP2022169589A (ja) | 2022-11-09 |
| JP7203426B2 (ja) | 2023-01-13 |
| WO2018050848A1 (en) | 2018-03-22 |
| US20190194350A1 (en) | 2019-06-27 |
| CA3033694A1 (en) | 2018-03-22 |
| KR102469700B1 (ko) | 2022-11-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1123355T1 (el) | Αντισωματα εναντι cd73 και χρησεις εξ αυτων | |
| MX2020008795A (es) | Anti cuerpos anti tigit y usos de los mismos. | |
| EP4282878A3 (en) | Chimeric antigen receptors targeting bcma and methods of use thereof | |
| RU2021114500A (ru) | НАПРАВЛЕННОЕ ИНГИБИРОВАНИЕ TGFβ | |
| MX2019002664A (es) | Proteina de union a antigeno contra her3. | |
| MY171100A (en) | Anti-ceacam5 antibodies and uses thereof | |
| ZA202005259B (en) | Anti-ctla4 antibodies and methods of making and using the same | |
| WO2020076977A3 (en) | Dll3 single domain antibodies and therapeutic compositions thereof | |
| FI3303396T3 (fi) | Vasta-aineita ox40:ää vastaan ja niiden käyttöjä | |
| NZ713461A (en) | Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer | |
| WO2011147982A3 (en) | Monoclonal antibodies against her2 epitope | |
| UA113623C2 (uk) | Моноклональне антитіло проти інгібітору шляху тканинного фактора (tfpi) | |
| WO2019241893A3 (en) | Anti-her3 antibody and uses thereof | |
| UA115439C2 (uk) | Гуманізоване антитіло, яке розпізнає альфа-синуклеїн | |
| WO2016077734A3 (en) | Nk cells with an increased antibody-dependent cellular toxicity (adcc) against tumors | |
| MX2020012081A (es) | Anticuerpos totalmente humanos contra ox40, metodo para preparar los mismos y su uso. | |
| WO2017060322A3 (en) | Ptefb-inhibitor-adc | |
| UA118354C2 (uk) | Антитіло до рецептора колонієстимулювального фактора (кфс-1r) | |
| WO2015161267A3 (en) | Humanized and chimeric monoclonal antibodies to cd99 | |
| EA201790341A1 (ru) | Анти-ск8 антитела для применения в лечении рака | |
| WO2015191590A3 (en) | Combination therapies targeting tumor-associated stroma or tumor cells and microtubules | |
| EP3854875A4 (en) | HUMAN MONOCLONAL ANTIBODY BINDING SPECIFICALLY TO HUMAN HMGB1, AND PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF ALZHEIMER'S DISEASE CONTAINING SUCH HUMAN MONOCLONAL ANTIBODY | |
| RU2015147913A (ru) | Антитело против рецептора эпидермального фактора роста | |
| WO2015191602A3 (en) | Combination therapies targeting tumor-associated stroma or tumor cells | |
| WO2015191610A3 (en) | Combination therapies using agents that target tumor-associated stroma or tumor cells and other pathways |